( Aesthetic Medicine, Dermatology, Plastic Surgery, (GLP-1)
Retatrutide Produces Greatest Weight Loss
A systematic review of 26 randomized controlled trials (RCTs) finds that among glucagon-like peptide 1 (GLP-1) receptor agonists and co-agonists on the market or still being investigated, the experimental drug retatrutide (Eli Lilly and Company) produces the greatest weight loss.
The review, conducted by researchers at McGill University, Montreal, Quebec, Canada, examined three commercially available medications in the class and nine that have not yet received regulatory approval.
In healthy adults with overweight or obesity who did not have diabetes, the highest mean reductions in relative and absolute body weight were achieved with once-weekly triple glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 and glucagon receptor agonist retatrutide, followed by the dual GIP/GLP-1 agonist tirzepatide (Eli Lilly and Company) and lastly by the GLP-1 agonist semaglutide (Novo Nordisk), according to the authors.
A systematic review of 26 randomized controlled trials (RCTs) finds that among glucagon-like peptide 1 (GLP-1) receptor agonists and co-agonists on the market or still being investigated, the experimental drug retatrutide (Eli Lilly and Company) produces the greatest weight loss.
The review, conducted by researchers at McGill University, Montreal, Quebec, Canada, examined three commercially available medications in the class and nine that have not yet received regulatory approval.
In healthy adults with overweight or obesity who did not have diabetes, the highest mean reductions in relative and absolute body weight were achieved with once-weekly triple glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 and glucagon receptor agonist retatrutide, followed by the dual GIP/GLP-1 agonist tirzepatide (Eli Lilly and Company) and lastly by the GLP-1 agonist semaglutide (Novo Nordisk), according to the authors.
No comments:
Post a Comment
id="blogfeeds"><$BlogFeedsVertical$>
id="postfeeds"><$BlogItemFeedLinks$>